Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: Mechanism and relationship to antibody isotype

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 791-801

  Lendvai, Nikoletta ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,5A,6 TETRAHYDRO 6 HYDROXY 3 HYDROXYMETHYL 2 METHYL 3,10A BIS(METHYLTHIO)PYRAZINO[1,2 A]INDOLE 1,4 DIONE; ANTIGEN; BEPAFANT; EPITOPE; FC RECEPTOR; FUNGUS ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18B7; RECEPTOR ANTIBODY; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG FATALITY; FEMALE; HEMATOCRIT; HEMOCONCENTRATION; HEMODYNAMICS; HISTOPATHOLOGY; HYPOTENSION; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHOCK;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, FUNGAL; B-LYMPHOCYTES; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED C57BL; POLYSACCHARIDES; RATS;

EID: 0032824712     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314946     Document Type: Article

References (62)

1. 1. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-702.
2. 2. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-61.
3. 3. Bleeker WK, Agterberg J, Rigter G, van Rooijen N, Bakker JC. Key role of macrophages in hypotensive side effects of immunoglobulin preparations: studies in an animal model. Clin Exp Immunol 1989;77:338-44.
4. 4. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:1811-26.
5. 5. Moxon ER. Haemophilus influence. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:2039-45.
6. 6. Lee SC, Casadevall A. Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clin Infect Dis 1996;23:194-5.
7. 7. Dong ZM, Murphy JW. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun 1995;63:770-8.
8. 8. Delfino D, Cianci L, Migliardo M, et al. Tumor necrosis factor inducing activities of Cryptococcus neoformans components. Infect Immun 1996; 64:5199-204; erratum, 1997;65:1991.
9. 9. Delfino D, Cianci L. Lupis E, et al. Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect Immun 1997;65:2454-6.
10. 10. Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, Kozel TR. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun 1996;64:2897-903.
11. 11. Dong ZM, Murphy JW. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest 1996;97:689-98.
12. 12. Dong ZM, Murphy JW. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun 1997;65:557-63.
13. 13. Hirano A, Zimmerman HM, Levine S. Fine structure of cerebral fluid accumulation. VI. Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendroglia. Arch Neurol 1965;12:189-96.
14. 14. Pettoello-Mantovani M, Casadevall A, Kollmann TR, Rubinstein A, Goldstein H. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 1992;339:21-3.
15. 15. Spitzer ED, Sptizer SG, Freundlich LF, Casadevall A. Persistence of the initial infection in recurrent cryptococcal meningitis. Lancet 1993;341: 595-6.
16. 16. Casadevall A, Cleare W, Feldmesser M, et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 1998;42:1437-46.
17. 17. Gordon MA, Lapa E. Serum protein enhancement of antibiotic therapy in cryptococcosis. J Infect Dis 1964;114:373-7.
18. 18. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991;163:1114-20.
19. 19. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994;38:580-7.
20. 20. Mukherjee J, Feldmesser M, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother 1995;39:1398-405.
21. 21. Feldmesser M, Mukherjee J, Casadevall A. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro. J Antimicrob Chemother 1996;37:617-22.
22. 22. Savoy AC, Lupan DM, Manalo PB, et al. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun 1997;65:1800-7.
23. 23. Gordon MA, Casadevall A. Serum therapy for cryptococcal meningitis. Clin Infect Dis 1995;21:1477-9.
24. 24. Goldman DL, Lee SC, Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun 1995;63:3448-53.
25. 25. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 1992;165:1086-93.
26. 26. Mukherjee J, Casadevall A, Scharff MD. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan tetanus toxoid conjugate immunization. J Exp Med 1993;177:1105-16.
27. 27. Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 1995;154:1810-6.
28. 28. Casadevall A, DeShaw M, Fan M, Dromer F, Kozel TR, Pirofski LA. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun 1994;62:3864-72.
29. 29. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979;150: 580-96.
30. 30. Franzot SP, Mukherjee J, Cherniak R, Chen LC, Hamdan JS, Casadevall A. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun 1998;66:89-97.
31. 31. Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996;23:82-90.
32. 32. Cherniak R, Reiss E, Turner S. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr Res 1982;103:239-50.
33. 33. Casadevall A, Mukherjee J, Scharff MD. Monoclonal antibody based EL1-SAs for cryptococcal polysaccharide. J Immunol Methods 1992;154: 27-35.
34. 34. Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 1994;62:4755-61.
35. 35. Aragnol D, Leserman LD. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA 1986;83: 2699-703.
36. 36. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010-8.
37. 37. Okamoto M, Yoshida K, Uchida I, Kohsaka M, Aoki H. Studies of platelet activating factor (PAF) antagonists from microbial products. II. Pharmacological studies of FR-49175 in animal models. Chem Pharm Bull 1986;34:345-8.
38. 38. Adamson JW. The myeloproliferative diseases. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. Harrison's principles of internal medicine. 11th ed. New York: McGraw-Hill, 1987;2: 1527-33.
39. 39. Weigle WO, Cochrane CG, Dixon FJ. Anaphylactogenic properties of soluble antigen-antibody complexes in the guinea pig and rabbit. J Immunol 1960;85:469-77.
40. 40. Weigle WO. Elimination of antigen-antibody complexes from sera of rabbits. J Immunol 1958;81:204-13.
41. 41. Benacerraf B, Sebestyen M, Cooper NS. The clearance of antigen antibody complexes from the blood by the reticulo-endothelial system. J Immunol 1959;82:131-7.
42. 42. Hazenbos WL, Ingmar AFM, Meyer D, et al. Murine IgG1 complexes trigger immune effector functions predominantly via FcγRIII (CD16). J Immunol 1998;161:3026-32.
43. 43. Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994;62: 1079-88.
44. 44. Nussbaum G, Yuan R, Casadevall A, Scharff MD. Immunoglobulin G3 blocking antibodies to Cryptococcus neoformans. J Exp Med 1996;183: 1905-9.
45. 45. Yuan RR, Casadevall A, Oh J, Scharff MD. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci USA 1997;94:2483-8.
46. 46. Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J Exp Med 1998;187:641-8.
47. 47. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by an anti Cryptococcus neoformans monoclonal antibody. Infect Immun 1987;55:749-52.
48. 48. Gavin AL, Barnes N, Dijstelbloem HM, Hogarth PM. Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol 1998;160: 20-3.
49. 49. Diamond B, Yelton DE. A new Fc receptor on mouse macrophages binding IgG3. J Exp Med 1981;153:514-9.
50. 50. Lendvai N, Casadevall A, Liang Z, Goldman DL, Mukherjee J, Zuckier L. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis 1998;177:1647-59.
51. 51. Casadevall A, Scharff MD. The mouse antibody response to infection with Cryptococcus neoformans: Vh and Vl usage in polysaccharide binding antibodies. J Exp Med 1991;174:151-60.
52. 52. Heuer HO. Effect of the hetrazepinoic platelet-activating factor antagonist Bepafant (WEB 2170) in models of active and passive anaphylaxis in miee and guinea pigs. Lipids 1991;26:1374-80.
53. 53. Heuer HO. Inhibition of active anaphylaxis in mice and guinea pigs by the new hetrazepinoic PAF antagonist bepafant (WEB 2170). Eur J Pharmacol 1991;199:157-63.
54. 54. Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther 1990;255:962-8.
55. 55. Feuerstein G, Siren AL. Platelet-activating factor and shock. Prog Biochem Pharmacol 1988;22:181-90.
56. 56. Vargaftig BB, Lefort J, Chignard M, Benveniste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1980;65:185-92.
57. 57. Amiel ML, Duquenne C, Benveniste J, Testart J. Platelet aggregating activity in human embryo culture media free of PAF-acether. Hum Reprod 1989;4: 327-30.
58. 58. Namm DH, Tadepalli AS, High JA. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. Thromb Res 1982;25:341-50.
59. 59. Scodras JM, Betteridge KJ, Croy BA, Johnstone IB, Rieger D. Failure to detect platelet-activating factor using the splenectomized mouse bioassay. J Reprod Fertil 1991;92:483-94.
60. 60. Keefer CL, Camoratto AM, Langford KG. Detection of synthetic and embryo-derived platelet-activating factor by the splenectomized mouse assay. Biol Reprod 1989;40(Suppl):67.
61. 61. Young JM, Maloney PJ, Jubb SN, Clark JS. Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse. Prostaglandins 1985;30:545-51.
62. 62. Vasquez-Bravo YL, Russo M, Jancar S. Differential sensitivity of mouse strains to platelet activating factor-induced vasopermeability and mortality: effect of antagonists. J Lipid Mediat 1993;8:135-44.